Clinical Trial Update: Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating bazedoxifene acetate as a remyelinating therapy for multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Bazedoxifene Acetate (bazedoxifene)

Snippet

Sponsor: Riley Bove, MD | Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Status: COMPLETED